Metabolic state and survival in patients with amyotrophic lateral sclerosis

Completed

Conditions: amyotrophic lateral sclerosis (ALS)
motor neuron disease (MND)
10029317

Registration Number: NL-OMON50744

Lead Sponsor: Afdeling Neurologie

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 234

Inclusion Criteria

For patients only (N = 78): meeting the El Escorial criteria for definite,
probable, probable laboratory supported or possible ALS, For controls only (N =
78): diagnosis with neurological syndrome within the range of peripheral
polyneuropathies with sensorimotor or motor fiber involvement. Or other motor
neuron disease (primary lateral sclerosis, progressive muscular atrophy,
progressive bulbar palsy or pseudobulbar palsy) , Asymptomatic carriers and
family members (N = 2x39): absence of any neurological symptom associated with
ALS., For family members, non-carriers and carriers, of any related gene to
ALS: absence of any neurological symtpoms associated with ALS. , All subjects:
>= 18 years of age

Exclusion Criteria

All subjects:
1.2. Participants < 18 years of age
2.3. Participants are not able to lay down for at least one hour, without any
difficulties of swallowing or breathing.
3.4. Participants with tracheostomy or other assisted ventilation in the
preceding 3 months., Neurological Controls, asymptomatic carriers, carriers of
any other gene related to ALS and family members of ALS patients with a
suspected genetic background of ALS (familial ALS):
7.6. Patients with peripheral polyneuropathy with only sensory fiber
involvement (i.e. human immunodeficiency virus or vitamin B5 toxicity)
8.7. Patients with peripheral mononeuropathy (i.e. compression or entrapment
neuropathies)

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main endpoint in the study will be disease progression, expressed as change<br /><br>from baseline on the revised Amyotrophic Lateral Sclerosis Functional Rating<br /><br>Scale (ALSFRS-R)</p><br>

Secondary Outcome Measures